Literature DB >> 10598204

Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989.

I D Hay1, E J Bergstralh, C S Grant, B McIver, G B Thompson, J A van Heerden, J R Goellner.   

Abstract

BACKGROUND: The pathologic tumor-node-metastasis (pTNM) system is universally used to define the extent of disease in human malignancies. This study evaluated the impact of initial therapy on cause-specific mortality (CSM) rates and recurrence rates in pTNM stage III papillary thyroid carcinoma.
METHODS: Three hundred patients (median age, 58 years) were followed on average for 14 postoperative years. Of these, 246 patients (82%) had complete primary tumor resection; 208 patients (69%) had nodal metastases; 161 (54%) had locally invasive primary tumors; 45 patients (15%) underwent initial unilateral lobectomy (UL). Bilateral lobar resection (BLR) accounted for 242 patients (near-total, 54%; total thyroidectomy, 23%).
RESULTS: The 30-year rates for CSM, distant metastases, nodal metastases, and local recurrence (LR) were 29%, 22%, 19%, and 16%, respectively. The 20-year rates for CSM were significantly higher (50% vs 14%) when primary tumor was incompletely resected (P = .0001). After complete resection, 20-year rates for CSM and LR after BLR were 12% and 10%, respectively, which were significantly lower (P < .05) than the 23% and 26% rates seen after UL. There were no significant differences in nodal metastases or distant metastases rates between UL and BLR (P > .4). The 20-year LR rate after total thyroidectomy (13%) was not different (P = .5) from the 11% seen after near-total thyroidectomy.
CONCLUSIONS: In this nonrandomized evaluation of patients with pTNM stage III papillary thyroid carcinoma, the extent of primary thyroid resection appeared to significantly impact CSM and LR but did not apparently influence regional or distant metastasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598204     DOI: 10.1067/msy.2099.101435

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Conservative management of well-differentiated thyroid cancer.

Authors:  Mazen Hassanain; Marvin Wexler
Journal:  Can J Surg       Date:  2010-04       Impact factor: 2.089

2.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

3.  Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer.

Authors:  Carlos A Benbassat; Sara Mechlis-Frish; Dania Hirsch
Journal:  World J Surg       Date:  2006-06       Impact factor: 3.352

4.  Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma.

Authors:  Xi Wei; Ying Li; Sheng Zhang; Ming Gao
Journal:  Tumour Biol       Date:  2014-05-27

Review 5.  Recurrence of papillary thyroid cancer after optimized surgery.

Authors:  Clive S Grant
Journal:  Gland Surg       Date:  2015-02

6.  Impact of prophylactic central neck lymph node dissection on early recurrence in papillary thyroid carcinoma.

Authors:  Tracy-Ann Moo; Julie McGill; John Allendorf; James Lee; Thomas Fahey; Rasa Zarnegar
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

7.  Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006.

Authors:  Clive S Grant; John M Stulak; Geoffrey B Thompson; Melanie L Richards; Carl C Reading; Ian D Hay
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

8.  Microscopic regional lymph node status in papillary thyroid carcinoma with and without lymphadenopathy and its relation to outcomes.

Authors:  Nobuyuki Wada; Nobuyasu Suganuma; Hirotaka Nakayama; Katsuhiko Masudo; Yasushi Rino; Munetaka Masuda; Toshio Imada
Journal:  Langenbecks Arch Surg       Date:  2007-02-16       Impact factor: 3.445

9.  [The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors].

Authors:  Joanna Kłubo-Gwieździńska; Roman Junik
Journal:  Endokrynol Pol       Date:  2008 Mar-Apr       Impact factor: 1.582

10.  Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.

Authors:  Mohamed Abdelgadir Adam; John Pura; Lin Gu; Michaela A Dinan; Douglas S Tyler; Shelby D Reed; Randall Scheri; Sanziana A Roman; Julie A Sosa
Journal:  Ann Surg       Date:  2014-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.